Summary
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
Description
THE PHARMACEUTICAL MARKET: SWITZERLAND - REVIEW
In size, the Swiss pharmaceutical market is similar to Greece; in per capita terms, it is the highest in the Western European region. Switzerland has a history of having a buoyant pharmaceutical market driven by the propensity to prescribe new and innovative medicines, especially in the hospital sector. Although the pharmaceutical market will continue to expand, low growth is projected between 2011 and 2016, due to price pressures from greater generic prescribing and general cost-control measures. The biologic sector is an area of potential growth in Switzerland. In November 2011, UCB announced that it will double its workforce at its bioproduction facility in Bulle by the time the plant opens in 2015.
The Swiss pharmaceutical industry is highly advanced and has long had an international reputation for the quality of its production and research. Two local companies dominate the sector; Novartis and Roche. They are both prominent in the domestic market, although the majority of their sales are earned outside Switzerland. In January 2012, Novartis announced it had reversed its decision to close a plant in Nyon and was going to scale down planned job cuts in Basel. In November 2011, Roche opened a new R&D centre in Basel.
By international standards, the Swiss generic market remains uncompetitive. Over 70% of generic sales are made by two companies; Mepha, owned by the Swiss arm of Teva, and Sandoz. A more competitive environment would almost certainly lead to lower price levels. However, the government's policy of period price reductions may prove counterproductive in this regard, by making the market less attractive for new players and entrenching the position of existing manufacturers. In December 2011, Acino announced it was to acquire the Mepha site in Aesch, including production and R&D facilities. In November 2011, Stada Arzneimittel signed a deal to acquire Spirig Pharma's generic business.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
The Pharmaceutical Market: Switzerland published by Espicom Business Intelligence in January 31, 2013. This report consists of 85 Pages and the price starts from US $ 1295.
The contents of this page may be different from the latest version. Please contact us for details.
